Ashion Analytics, Phoenix, Ariz, has launched the Genomic Enabled Medicine (GEM) cancer panel, to assist doctors in treating patients with cancer by producing a detailed genomic analysis.
Employing tumor-germline subtraction technology, the cancer panel covers the coding regions of 562 cancer-related genes, and also captures copy number events and structural variations. Results are delivered within 2 weeks. A team of oncology physician experts—each with subspecialty expertise in a broad range of cancer types—is available to provide physician support by consultation.
To support research studies and clinical trials, Ashion Analytics provides expanded whole-exome sequencing with its GEM-GW test, which also includes analysis of copy number events and structural variation, as well as RNA sequencing.
Michael Demeure, MD, MBA, Ashion Analytics.
“Our understanding of genomics today is fundamentally changing the way we view and treat cancer, and we believe the future holds even greater promise,” says Michael Demeure, MD, MBA, executive vice president and general manager of Ashion Analytics. “As a physician who continues to treat cancer patients, I see every day the critical need to develop better diagnostics as well as new, more effective, and less toxic treatment options. This unmet need drives all our efforts at Ashion Analytics.”
Ashion Analytics is a subsidiary of Ashion PMed Management LLC.
“We believe a higher form of medicine is at hand that will provide medical institutions with the means to use the very latest in genetic technology to improve the lives of their patients,” says Edgar Staren, MD, PhD, MBA, CEO of Ashion PMed Management LLC.
For more information, visit Ashion Analytics.
